| Size | Price | |
|---|---|---|
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Xylitol is a pentose sugar alcohol (pentose sugar alcohol) with a meso configuration, obtained by reducing the carbonyl group of xylose. It can be used as a sweetener, allergen, hapten, human metabolite, algal metabolite, Saccharomyces cerevisiae metabolite, and mouse metabolite. Ribitol is a metabolite found in or produced by Escherichia coli (K12, MG1655 strains). Xylitol has also been reported to be present in Rubus parvifolius, with relevant data available. Xylitol is a pentose sugar alcohol obtained by reducing the carbonyl group of xylose. Its sweetness is comparable to sucrose, and it can be used as a non-cariogenic sweetener. See also: Xylitol (note moved to).
Drug Indications Treatment of limb-girdle muscular dystrophy |
| Molecular Formula |
C5H12O5
|
|---|---|
| Molecular Weight |
152.1458
|
| Exact Mass |
152.068
|
| CAS # |
87-99-0
|
| Related CAS # |
Xylitol-5-13C;Xylitol-1-13C;Xylitol-2-13C;Xylitol-d7
|
| PubChem CID |
6912
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
494.5±40.0 °C at 760 mmHg
|
| Melting Point |
94-97 °C(lit.)
|
| Flash Point |
261.9±21.9 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
-3.77
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
76.1
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C([C@H](C([C@H](CO)O)O)O)O
|
| InChi Key |
HEBKCHPVOIAQTA-NGQZWQHPSA-N
|
| InChi Code |
InChI=1S/C5H12O5/c6-1-3(8)5(10)4(9)2-7/h3-10H,1-2H2/t3-,4+,5?
|
| Chemical Name |
(2S,4R)-pentane-1,2,3,4,5-pentol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~854.42 mM)
H2O : ~110 mg/mL (~722.97 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.25 mg/mL (21.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.25 mg/mL (21.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.25 mg/mL (21.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (328.62 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5725 mL | 32.8623 mL | 65.7246 mL | |
| 5 mM | 1.3145 mL | 6.5725 mL | 13.1449 mL | |
| 10 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04966299
Conditions:Insulin Resistance|Glucose Tolerance|Body Composition|Gastrointestinal Tolerance|Thrombocyte Aggregation|Blood p-Selectin|Blood Erythritol|Blood XylitolLink: https://clinicaltrials.gov/ct2/show/NCT04731363
Conditions:Cardiovascular Risk FactorLink: https://clinicaltrials.gov/ct2/show/NCT05852587
Conditions:Inflammatory Bowel Diseases|Clostridioides Difficile Infection
Title:Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease
Status:Not yet recruiting
updateDate:2025-12-16
Ctid:NCT06799039
Link: https://clinicaltrials.gov/ct2/show/NCT06799039
Conditions:Inflammatory Bowel Disease (IBD)|Clostridioides Difficile InfectionLink: https://clinicaltrials.gov/ct2/show/NCT05775848
Conditions:Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)Link: https://clinicaltrials.gov/ct2/show/NCT04800874
Conditions:LGMD2ILink: https://clinicaltrials.gov/ct2/show/NCT05671965
Conditions:Energy Intake|Gastrointestinal Hormones|Glycemic Control|Appetite|SatiationLink: https://clinicaltrials.gov/ct2/show/NCT02592382
Conditions:Otitis MediaLink: https://clinicaltrials.gov/ct2/show/NCT03229551
Conditions:Chronic Rhinosinusitis|Rhinosinusitis|Sinusitis|Drain Sinus|Endoscopic Sinus Surgery|Biofilms|Bacterial OvergrowthLink: https://clinicaltrials.gov/ct2/show/NCT04117477
Conditions:Allogeneic Hematopoietic Cell TransplantationLink: https://clinicaltrials.gov/ct2/show/NCT04585061
Conditions:Anxiety|PainLink: https://clinicaltrials.gov/ct2/show/NCT00928135
Conditions:Cystic FibrosisLink: https://clinicaltrials.gov/ct2/show/NCT04399161
Conditions:Cariostatic Agents|MouthwashesLink: https://clinicaltrials.gov/ct2/show/NCT01355796
Conditions:Cystic FibrosisLink: https://clinicaltrials.gov/ct2/show/NCT03039478
Conditions:Physiological Satiation MechanismsLink: https://clinicaltrials.gov/ct2/show/NCT00924404
Conditions:Chronic SinusitisLink: https://clinicaltrials.gov/ct2/show/NCT02823249
Conditions:Endocrine System DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT02563847
Conditions:Endocrine System DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT01528969
Conditions:Bacterial InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT02274636
Conditions:GERDLink: https://clinicaltrials.gov/ct2/show/NCT01647737
Conditions:Xerostomia|Sjogren Syndrome|Dry MouthLink: https://clinicaltrials.gov/ct2/show/NCT02036151
Conditions:Dental Caries and Streptococcus Mutans CountLink: https://clinicaltrials.gov/ct2/show/NCT00638677
Conditions:Dental Caries|Infectious DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT01561508
Conditions:Diabetes MellitusLink: https://clinicaltrials.gov/ct2/show/NCT01578603
Conditions:Dental Plaque|Saliva Altered|GingivitisLink: https://clinicaltrials.gov/ct2/show/NCT01468727
Conditions:Dental CariesLink: https://clinicaltrials.gov/ct2/show/NCT00393055
Conditions:Dental CariesLink: https://clinicaltrials.gov/ct2/show/NCT01062633
Conditions:Dental CariesLink: https://clinicaltrials.gov/ct2/show/NCT00530153
Conditions:Eating|Oral HealthProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
